Your session is about to expire
← Back to Search
This trial is testing a new treatment for dry eye disease that uses a combination of light and radiofrequency energy. The goal is to see if it is safe and effective.
- Meibomian Gland Dysfunction
- Dry Eye Syndrome
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current participant count for this investigation?
"Correct. According to clinicaltrials.gov, this research endeavour is currently in the process of recruiting volunteers; it was posted on July 21st 2022 and most recently amended on August 1st 2022. The study necessitates 30 patients between two separate sites."
Is this research endeavor accepting participants that are above the age of 40?
"The criteria for enrollment for this trial requires that participants are between 22 and 85 years of age."
Is it possible to become an enrollee in this clinical trial?
"30 participants with meibomian gland dysfunction between 22 and 85 years old will be admitted in this trial. It is essential that these individuals are literate, possess moderate to severe dry eye symptoms (OSDI score ≥ 23), demonstrate MGD signs during biomicroscopy, have a mMGS value of 12 or higher for their lower eyelids, agree to comply with the conditions set by the study protocol, and fall within Fitzpatrick skin type I-IV."
Are there still open enrollment slots in this investigation?
"Evidenced by the clinicaltrials.gov website, this study is still recruiting participants. The original posting of the trial was on July 21st 2022 and a recent update occurred on August 1st 2022."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends